Zimmer Partners’s Viking Therapeutics VKTX Stock Holding History

Zimmer Partners’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-51,000	Closed	-$1.35M	–	193
2025 Q2	$1.35M	Buy	+51,000	New	+$1.34M	0.03%	136

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Zimmer Partners's VKTX Position: Q3 2025 in Review

Zimmer Partners sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 51,000 shares — an estimated $1.35M sold.

Zimmer Partners first reported a position in VKTX in Q2 2025 and held it in 1 quarter. The position peaked at $1.35M in Q2 2025. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

Zimmer Partners reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
Zimmer Partners sold 51,000 Viking Therapeutics shares in Q3 2025, an estimated $1.35M.
Zimmer Partners first reported a position in Viking Therapeutics in Q2 2025 and held it in 1 quarter.
Zimmer Partners's Viking Therapeutics position peaked at $1.35M in Q2 2025.
370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Zimmer Partners's 13F filing for Q3 2025, filed 14 Nov 2025.